Survey of Brentuximab Vedotin for treating pediatric Hodgkin Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study in Japan focuses on pediatric participants with Hodgkin lymphoma receiving Brentuximab Vedotin in combination with AVD treatment. The study aims to monitor and document side effects associated with Brentuximab Vedotin, particularly myelosuppression, peripheral neuropathy, and lung disorders. Participants will be treated according to their clinic's standard practices, and the study will last for 26 weeks, during which side effects will be closely observed and recorded. The study sponsor will provide guidelines for data collection but will not influence treatment decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Treatment-naive participants
2. CD30 positive participants
3. Participants treated with the study drug in combination with doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD).
4. Participants aged \< 18 years at the start of this drug.

Exclusion Criteria:

Participants with contraindications to the study drug.

Where it's running

• Takeda selected site
  Tokyo, Tokyo, Japan Recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BrECADD for stage 2B–III classical Hodgkin lymphoma

  This tests the BrECADD chemotherapy combination in adults 18–60 with stage 2B (with risk factors) or stage III classical Hodgkin lymphoma and uses ctDNA to help track treatment response.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07002216

• Combining brentuximab vedotin with standard chemotherapy for Hodgkin lymphoma in adults

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help adults with untreated Hodgkin lymphoma feel better and improve their treatment results.

  Recruiting at 5 sites Phase 4 Takeda · Vijayawada, Andhra Pradesh and 10 other locations · NCT06831370

• New treatment approach for relapsed or refractory Hodgkin lymphoma

  This study is testing a new treatment for people with relapsed or hard-to-treat Hodgkin lymphoma to see if combining certain therapies can help them live longer and feel better.

  Recruiting Phase 2/3 Hospital Regional de Alta Especialidad del Bajio · León, Guanajuato · NCT05595447

• Comparing new drugs to standard treatment for relapsed Hodgkin lymphoma

  This study is testing if new drugs Pembrolizumab and Brentuximab vedotin work better than standard treatment for people with relapsed Hodgkin lymphoma.

  Recruiting at 18 sites Phase 2 Canadian Cancer Trials Group · Concord, New South Wales and 17 other locations · NCT05180097

• Brentuximab vedotin for early stage Hodgkin lymphoma treatment

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help people with early-stage Hodgkin lymphoma do better in their treatment.

  Recruiting at 72 sites Phase 3 University College, London · Stanford, California and 71 other locations · NCT04685616

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.